You cannot register for this webinar

FDA guidance is clear that real world data (RWD) may be acceptable for regulatory approval when a randomised controlled trial is not feasible and the validity and trustworthiness of the real world study results are clearly demonstrated. To provide more operationalised guidance for meeting these standards, the presenters will share learnings from FDA use cases and ongoing demonstration projects.